4-Factor PCC (Kcentra) and Warfarin Reversal

Part of the ICU Emergencies Hub — browse every related guide in one place.

Updated July 2026  |  More ICU nursing guides →

Warfarin has been around for decades, and so has the wrong way to reverse it. For years the reflex for a bleeding warfarin patient was to hang units of fresh frozen plasma and wait — thawing, transfusing, volume-loading, and watching the INR crawl down over hours. Four-factor prothrombin complex concentrate changed the standard. It reverses the INR in minutes with a fraction of the volume. For the ICU nurse, the key is understanding why PCC plus IV vitamin K is the durable combination — and why one without the other fails.

Why warfarin needs replacement, not a decoy

Warfarin works by blocking vitamin K recycling, which starves the liver of its ability to make the vitamin K–dependent clotting factors: II, VII, IX, and X (plus proteins C and S). The patient's problem isn't a circulating drug to mop up — it's a deficiency of functional clotting factors. So reversal means replacing those factors. That's exactly what 4-factor PCC does: it's a concentrate of factors II, VII, IX, and X, delivered in a small volume.

Three- vs. four-factor matters: 4-factor PCC (Kcentra in the US) contains meaningful factor VII, while older 3-factor products are low in VII. For warfarin reversal you want the 4-factor product.

PCC vs. fresh frozen plasma

Both replace clotting factors, but they are not equivalent in an emergency:

For an emergent warfarin bleed — especially intracranial hemorrhage where every minute of ongoing bleeding costs brain tissue — PCC is favored precisely because it works fast and doesn't drown a fragile patient in volume.

The dosing logic

4-factor PCC for warfarin reversal is typically dosed by body weight and the presenting INR — a higher INR gets more units per kilogram — with a per-dose cap and usually a maximum body weight used in the calculation. You'll see the dose expressed in "units" of factor IX activity. The important nursing points: the dose is individualized (not one-size-fits-all), it's given as a relatively quick IV infusion, and the INR is rechecked afterward (often around 30 minutes post-infusion and again later) to confirm reversal and guide any repeat dosing.

The vitamin K half of the equation — don't skip it

Here is the single most important concept in warfarin reversal: PCC and IV vitamin K are given together, and each does a different job.

• PCC works immediately but wears off. The infused factors have limited half-lives — factor VII is especially short-lived. Within hours, those replacement factors decay.
• Warfarin is still in the body. A single dose of PCC doesn't remove warfarin; the drug keeps suppressing the patient's own factor production. So as the PCC-supplied factors fade, the INR climbs back up — a rebound — unless something restores the patient's own factor synthesis.
• IV vitamin K restarts native production. Given IV, vitamin K begins reversing warfarin's block over several hours and sustains the correction long after the PCC is gone. It's slow to start but durable — the mirror image of PCC.

Give PCC alone and the patient can re-anticoagulate within hours. Give vitamin K alone and the patient bleeds for hours while waiting for it to work. Together, PCC covers the immediate gap and vitamin K holds the line. IV (not oral or subcutaneous) vitamin K is used for emergent reversal; it's typically given as a slow infusion because rapid IV push has been associated with rare anaphylactoid reactions — so watch the patient during administration.

Thrombotic risk

PCC is a concentrate of clotting factors, so it carries a boxed warning for thromboembolic events. The patient was anticoagulated for a reason, and now you've handed them a bolus of clotting factors on top of removing their anticoagulation. Watch for new DVT, PE, stroke, or MI. This risk is weighed against the very real, immediate danger of the bleed — in a life-threatening hemorrhage the bleed usually wins the argument — but it's why PCC isn't handed out casually and why the team plans to resume appropriate anticoagulation once it's safe.

Where PCC fits beyond warfarin

Although its on-label US indication is warfarin (vitamin K antagonist) reversal, 4-factor PCC is also used off-label for factor Xa inhibitor bleeding (apixaban, rivaroxaban) at many institutions — it's fast, available, and doesn't cause the heparin-resistance problem that andexanet can. It is not the reversal for dabigatran (that's idarucizumab) or heparin (that's protamine). Knowing PCC's warfarin role and its off-label Xa role explains why you'll see it ordered in more than one reversal scenario.

The nursing bottom line

Warfarin depletes clotting factors II, VII, IX, and X, so reversal means replacing them — and 4-factor PCC does that fast, in a small volume, without the delay and fluid load of FFP. But PCC alone rebounds, because it wears off while warfarin lingers. The durable fix is PCC plus IV vitamin K: PCC for the immediate correction, vitamin K to restart the patient's own factor production and keep the INR down. Dose is weight- and INR-based, thrombotic risk is real (boxed warning), and the INR is rechecked to confirm reversal. If you remember one thing, remember that vitamin K is not optional.

Related: idarucizumab (Praxbind) for dabigatran reversal, andexanet alfa for factor Xa inhibitor reversal, and anticoagulation reversal in intracranial hemorrhage.